Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres
- PMID: 28758319
- DOI: 10.1111/ijcp.12972
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres
Abstract
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC. However, multiple factors including contraindications, technical considerations and treatment-related toxicities pose significant challenges in achieving favourable treatment outcomes, underscoring the need for a paradigm shift in managing these patients. In 2002, yttrium-90 (Y-90) resin microspheres was approved by the U.S. Food and Drug Administration (FDA) for the treatment of unresectable metastatic colorectal cancer to the liver with adjuvant floxuridine chemotherapy. However, thousands of patients with unresectable HCC have also been treated with resin Y-90. For over two decades, several small-scale prospective trials and retrospective studies have investigated and reported on the efficacy of locoregional selective internal radiation therapy (SIRT) with Y-90 microspheres in treating unresectable HCC. Although it is currently a treatment option for intermediate-stage HCC patients, mainstream clinical application of resin Y-90 has been largely limited because of the lack of sufficient clinical data from a randomised controlled trial. This could change with the imminent announcement of results from the phase 3 Sorafenib vs Radioembolization in Advanced Hepatocellular carcinoma (SARAH) trial. To provide the foundation and context for interpreting results from the SARAH trial, this article provides an overview of treatment modalities and current challenges in managing unresectable HCC. There is also a review of key prospective and retrospective studies evaluating the use of Y-90 SIRT, specifically Y-90 resin microspheres in unresectable HCC, which led to the development of the SARAH trial.
Methods: To identify relevant publications, the PubMed database was queried using one or more of the following search terms alone or in combination with Boolean operators: epidemiology, hepatocellular, hepatocellular cancer, hepatocellular carcinoma, unresectable, radioembolisation, selective internal radiation therapy, SIR-Spheres, yttrium 90, TACE, and sorafenib. The results were sorted or filtered by "Author", "Publication dates" or "Article types" to identify articles relevant to each section of the review. To ensure that information on ongoing clinical trials involving Y-90 resin was included, we conducted a search on "ClinicalTrials.gov", by combining the search terms "HCC" OR "hepatocellular carcinoma" with "Y 90" OR "yttrium 90" OR "radioembo", and screened for studies that involved treatment with Y-90 resin microspheres.
Keywords: HCC; SIRT; SIR-Spheres; Y90; hepatocellular carcinoma/cancer; resin; sorafenib; transarterial chemoembolisation; transarterial radioembolisation; unresectable; yttrium-90.
© 2017 John Wiley & Sons Ltd.
Similar articles
-
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
-
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.Cochrane Database Syst Rev. 2020 Jan 24;1(1):CD011313. doi: 10.1002/14651858.CD011313.pub3. Cochrane Database Syst Rev. 2020. Retraction in: Cochrane Database Syst Rev. 2020 Nov 16;11:CD011313. doi: 10.1002/14651858.CD011313.pub4. PMID: 31978267 Free PMC article. Retracted.
-
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Jan 24;1:CD011313. doi: 10.1002/14651858.CD011313.pub3. PMID: 26905230 Updated. Review.
-
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474. Trials. 2014. PMID: 25472660 Free PMC article. Clinical Trial.
-
Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.Recent Results Cancer Res. 2013;190:207-24. doi: 10.1007/978-3-642-16037-0_14. Recent Results Cancer Res. 2013. PMID: 22941023 Review.
Cited by
-
Selective Internal Radiotherapy Alters the Profiles of Systemic Extracellular Vesicles in Hepatocellular Carcinoma.Int J Mol Sci. 2023 Aug 7;24(15):12512. doi: 10.3390/ijms241512512. Int J Mol Sci. 2023. PMID: 37569887 Free PMC article.
-
Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma.Cancers (Basel). 2023 Mar 14;15(6):1748. doi: 10.3390/cancers15061748. Cancers (Basel). 2023. PMID: 36980634 Free PMC article. Review.
-
Evaluation of Therapeutic Efficacy and Imaging Capabilities of 153Sm2O3-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model.Pharmaceutics. 2023 Feb 6;15(2):536. doi: 10.3390/pharmaceutics15020536. Pharmaceutics. 2023. PMID: 36839858 Free PMC article.
-
Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides.Pharmaceuticals (Basel). 2022 Oct 28;15(11):1339. doi: 10.3390/ph15111339. Pharmaceuticals (Basel). 2022. PMID: 36355512 Free PMC article. Review.
-
Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells.Cancers (Basel). 2022 May 12;14(10):2381. doi: 10.3390/cancers14102381. Cancers (Basel). 2022. PMID: 35625986 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous